ACP-105

ACP-105
Legal status
Legal status	US: Investigational new drug;
Identifiers
	IUPAC name 2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbenzonitrile;
CAS Number	1048998-11-3;
PubChem CID	11507567;
ChemSpider	9682364;
ChEMBL	ChEMBL3410856;
CompTox Dashboard (EPA)	DTXSID101134942 ;
Chemical and physical data
Formula	C16H19ClN2O
Molar mass	290.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1Cl)C#N)N2C3CCC2CC(C3)(C)O;
	InChI InChI=1S/C16H19ClN2O/c1-10-14(6-3-11(9-18)15(10)17)19-12-4-5-13(19)8-16(2,20)7-12/h3,6,12-13,20H,4-5,7-8H2,1-2H3; Key:OUEODVPKPRQETQ-UHFFFAOYSA-N;

ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline.^[1]^[2]^[3]^[4] The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186.^[3] ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).^[5]